4 Healthcare Stock Stories to Start a Week of Investment Wellness

In a Bloomberg Television interview Monday at the Asia-Pacific Economic Cooperation meeting in Bali, Chief Executive Chris Viehbacher said that the French drug maker will return to earnings growth in the fourth quarter following the loss of patent protection on nine drugs in the past three years which cut into profit. Viehbacher observed that, “We’ve just come through the deepest and most concentrated patent cliffs in the industry. Our view is that particularly in the fourth quarter, the company returns to growth for the next period.”